491 related articles for article (PubMed ID: 31836928)
1. Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.
Das S; Zhou D; Nichols WW; Townsend A; Newell P; Li J
Eur J Clin Pharmacol; 2020 Mar; 76(3):349-361. PubMed ID: 31836928
[TBL] [Abstract][Full Text] [Related]
2. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
[TBL] [Abstract][Full Text] [Related]
3. Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
Li J; Lovern M; Riccobene T; Carrothers TJ; Newell P; Das S; Talley AK; Tawadrous M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015049
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy.
Tichy E; Torres A; Bassetti M; Kongnakorn T; Di Virgilio R; Irani P; Charbonneau C
Clin Ther; 2020 May; 42(5):802-817. PubMed ID: 32349879
[TBL] [Abstract][Full Text] [Related]
5.
Stone GG; Bradford PA; Tawadrous M; Taylor D; Cadatal MJ; Chen Z; Chow JW
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071051
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.
Sy SKB; Zhuang L; Sy S; Derendorf H
Clin Pharmacokinet; 2019 May; 58(5):545-564. PubMed ID: 30097887
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.
Franzese RC; McFadyen L; Watson KJ; Riccobene T; Carrothers TJ; Vourvahis M; Chan PLS; Raber S; Bradley JS; Lovern M
Clin Pharmacol Ther; 2022 Mar; 111(3):635-645. PubMed ID: 34687548
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.
Falcone M; Viale P; Tiseo G; Pai M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935
[TBL] [Abstract][Full Text] [Related]
10. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
11. Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime.
Giri P; Patel H; Srinivas NR
Drug Res (Stuttg); 2019 May; 69(5):245-255. PubMed ID: 30296806
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
13. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of ceftazidime-avibactam versus meropenem in Indian patients with nosocomial pneumonia: Subset analysis from the REPROVE study.
Sathe P; Kamat S; Adhav C
Indian J Med Microbiol; 2021 Jul; 39(3):363-366. PubMed ID: 34045081
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS
J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
17. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups.
Li J; Lovern M; Green ML; Chiu J; Zhou D; Comisar C; Xiong Y; Hing J; MacPherson M; Wright JG; Riccobene T; Carrothers TJ; Das S
Clin Transl Sci; 2019 Mar; 12(2):151-163. PubMed ID: 30221827
[TBL] [Abstract][Full Text] [Related]
18. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
20. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
Cheng K; Newell P; Chow JW; Broadhurst H; Wilson D; Yates K; Wardman A
Drug Saf; 2020 Aug; 43(8):751-766. PubMed ID: 32602065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
